Inductive Bio

New York, New York, United States

AI drug discoveryDrug DiscoveryDrug DevelopmentLife Sciences

Inductive Bio is a healthcare startup focused on accelerating drug discovery through state-of-the-art artificial intelligence (AI) and generative chemistry. The company has developed an advanced ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) model that leverages a large, diverse dataset from a pre-competitive data consortium to provide reliable predictions across the chemical space. Key products include the Beacon-1 AI model, which offers real-time ADMET predictions, and the Compass software, designed to assist chemists with actionable recommendations and efficient molecule design. Inductive Bio emphasizes a collaborative approach, integrating medicinal chemists and machine learning engineers to optimize the drug design process, ensuring that compounds meet desirable properties while reducing time and costs associated with drug development. The company's platforms prioritize data security and confidentiality, meeting rigorous standards while optimizing the design cycle for high-quality compounds.